SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

UBS Sees More Challenges for Merck KGaA in 2027

Merck KGaA raised its full-year guidance again, while UBS analysts see a more challenging 2027 outlook, citing accelerating generic competition for Mavenclad and potential competition for Ogsiveo.

MRK

Related stories